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Diabetes mellitus (DM) is a risk factor for poor outcome in patients 
with COVID-19.1 However, the focus on mitigating the effects of 
SARS-CoV-2 has resulted in many routine healthcare services, in-
cluding blood test monitoring in conditions such as DM, being 
disrupted.
We recently explored the impact of the COVID-19 pandemic on 
DM diagnosis and management using routinely collected laboratory 
data on the key DM test, glycated haemoglobin (HbA1c).
We extracted HbA1c data from clinical laboratory infor-
mation systems at the University Hospitals of North Midlands 
(UHNM), St. Helens & Knowsley Hospitals (STHK), Salford 
Royal Foundation Trust (SRFT), Cambridge University Hospitals 
(CUH) and Warrington & Halton Hospitals (WHH) from October 
2017-September 2020 (representing 3.3 million people; ~4.8% of 
the UK population). We were particularly interested to compare 
the periods before and after the United Kingdom (UK) lockdown 
on 23 March 2020 and the related curtailment of usual National 
Health Service (NHS) activities in relation to routine programmed 
care, in order to focus resources on management of those people 
acutely unwell with COVID-19.
From these data (3 million tests), we calculated the monthly 
number of missed diagnostic/monitoring tests between 23 
March-30 September 2020). We compared the period leading up 
to 23 March 2020 (UK Lockdown) to the period post 23 March 
2020.
We showed that HbA1c tests dropped by 82%-88% in April 2020 
and had not reached expected volumes by September (Figure 1). 
During the 6-month period, in people with DM or at risk of DM, 
206 422 monitoring tests were missed. Of these, 23 466 (11.4%) 
had	 previous	 HbA1c	 values	 ≥59	 mmol/mol.	 The	 testing	 delay	 in	
this group would, on average, result in a mean increase in HbA1c 
of 5.7 mmol/mol (95% confidence interval (CI) 5.2-6.2mmol/mol) 
over and above that expected if monitoring were performed accord-
ing to NICE guidance.2-4 This estimate is based on the analysis of 
400 497 HbA1c tests in 79 409 individuals as previously described.4 
We found in that analysis that testing outside guidance on HbA1c 
monitoring frequency, is associated with a significant detrimental 
effect on diabetes control.
There were also an estimated 81 245 missed diagnostic tests. 
Of these, ~6105 (7.5%) would be expected to be in the pre- 
diabetes range (42-47 mmol/mol) and ~3633 (4.5%) with the diabe-
tes	range	(≥48	mmol/mol),	with	~1333 of these having HbA1c values 
of	≥76	mmol/mol.
Extrapolating this to the UK population, these data equate to 
missed monitoring tests in 489 000 people with sub-optimally- 
controlled diabetes, leading to missed glycaemic control targets with 
associated increased risk of complications, including symptomatic 
cardiovascular disease and renal impairment, with their associated 
excess mortality risk.5 These data also equate to ~127 000 missed 
pre-diabetes and 76 000 missed diabetes diagnoses, with conse-
quent delay in lifestyle advice and treatment initialisation as advised 
by NICE.2,4
We have previously shown that HbA1c testing at a 3 monthly 
interval was associated with a 3.8% reduction in HbA1c compared 
with a 1.5% increase observed with annual testing. Compared with 
annual monitoring, 3-monthly testing was associated with a halving 
of the proportion showing a significant rise in HbA1c (7-10 vs 15%-
20%).4 Thus, any perturbation of the system that results in disrup-
tion of testing protocols will likely result in many patients drifting 
above target glycaemia and in many of those above target HbA1c, 
remaining at that level. We accept that treatment decisions by cli-
nicians and patients are based on the combination of blood glucose 
readings (whether by standard finger prick or by continuous blood 
glucose monitoring) plus HbA1c.
This is not a worse case scenario, but rather based on real world 
large data in which all the factors described above are in play. Our find-
ings, in keeping with those of a recent study using general practice data,6 
illustrate the widespread collateral impact of implementing measures to 
mitigate the impact of COVID-19 in people with, or being investigated 
for DM. Ironically, failure to focus of the wider implications for people 
with DM and other groups with long-term conditions, may place them 
at increased risk of poor outcomes from SARS-CoV-2 infection itself, 
irrespective of the implications for their longer term health prospects.
This is an open access article under the terms of the Creative Commons Attribution- NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2021 The Authors. International Journal of Clinical Practice published by John Wiley & Sons Ltd












1The Benchmarking Partnership, Alsager, UK
2Department of Diabetes and Endocrinology, Salford Royal NHS 
Foundation Trust, Salford, UK
3The School of Medicine and Manchester Academic Health 
Sciences Centre, The University of Manchester, Manchester, UK
4Res Consortium, Andover, UK
5St. Helens & Knowsley Teaching Hospitals NHS Trust, Whiston 
Hospital, Prescot, UK
6Department of Clinical Biochemistry, The Royal Oldham 
Hospital, The Northern Care Alliance NHS Group, Oldham, UK
7School of Medicine, Keele University, Keele, Staffordshire, UK
8Department of Clinical Biochemistry, University Hospitals of 
North Midlands NHS Trust, Stoke-on-Trent, Staffordshire, UK
9Department of Diabetes and Endocrinology, University 
Hospitals of North Midlands NHS Trust, Stoke-on-Trent, 
Staffordshire, UK
10Centre for Health & Development, Staffordshire University, 
Stoke-on-Trent, Staffordshire, UK
11Department of Obstetrics & Gynaecology, University Hospitals 
of North Midlands NHS Trust, Stoke-on-Trent, Staffordshire, UK
12Department of Clinical Biochemistry, Cambridge University 
Hospitals NHS Foundation Trust, Addenbrooke's Hospital, 
Cambridge, UK
13Department of Pathology, Warrington & Halton Teaching 
Hospitals NHS Foundation Trust, Warrington, UK
Correspondence
Adrian Heald, Department of Diabetes and Endocrinology, 
Salford Royal NHS Foundation Trust, Salford, The School of 
Medicine and Manchester Academic Health Sciences Centre, 
The University of Manchester, Manchester, UK.
Email: adrian.heald@manchester.ac.uk
ORCID
Adrian H. Heald  https://orcid.org/0000-0002-9537-4050 
Anthony A. Fryer  https://orcid.org/0000-0001-8678-0404 
R E FE R E N C E S
 1. Muniangi-Muhitu H, Akalestou E, Salem V, Misra S, Oliver NS, Rutter 
GA. Covid-19 and Diabetes: A Complex Bidirectional Relationship. 
Front Endocrinol (Lausanne). 2020;11:582936.
F I G U R E  1   Month-by-month HbA1c test numbers across the five sites prior to and during the COVID-19 Impact Period
     |  3 of 3LETTER
 2. National Institute for Health and Care Excellence (NICE). Type 2 
diabetes in adults: management NICE guideline [NG 28]. 2015. 
https://www.nice.org.uk/guida nce/ng28. Accessed November 13, 
2020.
 3. Driskell OJ, Holland D, Waldron JL, et al. Reduced testing frequency 
for glycated hemoglobin, HbA1c, is associated with deteriorating dia-
betes control. Diabetes Care. 2014;37:2731-2737.
 4. Public Health Guideline [PH38]. National Institute for Health and 
Care Excellence (NICE). Type 2 diabetes: prevention in people at 
high risk; 2012. https://www.nice.org.uk/guida nce/ph38. Accessed 
November 13, 2020.
 5. Klein KR, Buse JB. The trials and tribulations of determining HbA1c tar-
gets for diabetes mellitus. Nat Rev Endocrinol. 2020;16:717-730.
 6. Carr MJ, Wright AK, Leelarathna L, et al. Impact of COVID-19 on the 
diagnoses, HbA1c monitoring and mortality in people with type 2 di-
abetes: a UK-wide cohort study involving 13 million people in primary 
care. https://www.medrx iv.org/conte nt/10.1101/2020.10.25.20200 
675v1.full.pdf. Accessed November 13, 2020.
